Pharmaceutical R&D powered by Global Business Services

With the average cost to develop a new drug rapidly increasing, there is a significant opportunity for pharmaceutical organisations to leverage Global Business Services (GBS) to act as a strategic transformation asset.

This report highlights key areas of opportunity across the R&D organisation that could be delivered from a GBS model. Additionally, it highlights key considerations for leaders to keep in mind as they embark on this journey including:

• A hyper-focus on patient experience
• Driving innovation with focused partnership models
• How to leverage the scale of GBS and harness its global talent pool